查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1888778

美国药局市场规模、份额和趋势分析报告：按产品类型、所有权和细分市场分類的预测（2025-2033 年）

U.S. Pharmacy Market Size, Share & Trends Analysis Report By Product Type (Prescription, OTC), By Type (Hospital Pharmacy, Retail Chains, ePharmacy), By Ownership, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

美国药局市场规模及趋势：

2024年美国药局市场规模估计为7,324.4亿美元，预计到2033年将达到17,070.2亿美元。

预计从 2025 年到 2033 年，该行业将以 9.91% 的复合年增长率成长。这一增长归因于慢性病的增加、处方药的高使用率以及该国老年人口的增长。

美国心臟协会 (AHA) 2023 年的一份报告显示，近一半 (48.6%) 的美国患有某种形式的心血管疾病，包括心臟疾病、心臟衰竭、中风或高血压。

目录

第一章 调查范围与调查方法

第二章执行摘要

第三章美国药局市场－产业展望

  • 市场体系展望
  • 市场动态
  • 法规环境和报销前景
  • 商业环境分析工具

第四章：美国药局市场：依产品类型分類的估算与趋势分析

  • 按产品类型分類的差异分析和市场份额分析（2024 年和 2033 年）
  • 美国药局市场规模及预测，依产品类型分類的预测
    • 处方药
    • 非处方药

第五章：美国药局市场：按类型分類的估算与趋势分析

  • 按类型分類的变异分析和市场份额分析（2024 年和 2033 年）
  • 美国药局市场规模及按类型分類的预测，2021-2033年
  • 美国药房市场：按类型分類的药房估计值（2021-2033 年）
  • 美国药房市场：按类型处方笺量预测（2021-2033 年）
  • 美国药局市场：按服务区域分類的预计处方笺量，2024 年（%）
  • 美国药局市场：处方笺量预测（以处方笺计），2024 年（%）
    • 零售连锁店
    • 超级市场药房
    • 医疗保健系统/医院药房
    • 独立药房
    • 邮购药房
    • 专科药房/中央配药房
    • 长期护理和国防药房
    • 网路药局
    • 其他的

第六章美国药局市场竞争分析

  • 公司分类
  • 2024年企业市场占有率预测分析
    • CVS Pharmacy
    • Walgreens Boots Alliance, Inc.
    • Scriptco Pharmacy
    • Walmart Pharmacy
    • Avita Pharmacy
    • The Kroger Co.
    • Albertsons Companies, Inc.
    • Costco Wholesale Corporation.
    • Sam's West, Inc.
Product Code: GVR-4-68040-044-6

U.S. Pharmacy Market Size & Trends:

The U.S. pharmacy market size was estimated at USD 732.44 billion in 2024 and is projected to reach at USD 1,707.02 billion by 2033, growing at a CAGR of 9.91% from 2025 to 2033. The growth is attributed to the rising prevalence of chronic diseases, the high utilization of prescription drugs, and the increasing elderly population in the country.

A report from the 2023 American Heart Association (AHA) indicates that nearly half of the U.S. population (48.6%) has some form of cardiovascular disease, including coronary heart disease, heart failure, stroke, and high blood pressure.

U.S. Pharmacy Market Report Segmentation

This report forecasts revenue growth, country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. pharmacy market report based on type, product type, and ownership.

  • Type Outlook (Revenue, USD Billion, 2021 - 2033)
  • Retail chains (e.g., Walgreens, CVS)
  • Supermarket pharmacies
  • Health system/hospital pharmacies
  • Independent pharmacies
  • Mail-order pharmacies
  • Specialty / central fill pharmacies
  • Long-term care and defense-related pharmacies
  • ePharmacy
  • Others
  • Product Type Outlook (Revenue, USD Billion, 2021 - 2033)
  • Prescription
  • OTC
  • Ownership Outlook (Revenue, USD Billion, 2021 - 2033)
  • Chain
  • Independent

Table of Contents

Chapter 1. Report Scope & Research Methodology

  • 1.1 Market Segmentation
    • 1.1.1 Segment Definition
      • 1.1.1.1 Product Type
      • 1.1.1.2 Type
  • 1.2 Estimates and Forecast Timeline
  • 1.3 Research Methodology
    • 1.3.1 Information Procurement
    • 1.3.2 Purchased Database
    • 1.3.3 Gvr's Internal Database
    • 1.3.4 Secondary Sources
    • 1.3.5 Primary Research
    • 1.3.6 Details Of Primary Research
  • 1.4 Information or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Three Pillars of Market Estimation
      • 1.6.1.1 Secondary Market Research
      • 1.6.1.2 Primary Market Intelligence
        • 1.6.1.2.1 In-Depth Interviews (IDIs)
        • 1.6.1.2.2 Online Survey Program
    • 1.6.2 Market Modeling & Forecasting
      • 1.6.2.1 Model 1: Volume-Price Analysis
        • 1.6.2.1.1 Step 1: Prescription volume estimation
        • 1.6.2.1.2 Channel-Wise Methodology
          • 1.6.2.1.2.1 Retail Chains (CVS, Walgreens, etc.)
          • 1.6.2.1.2.2 Supermarket Pharmacies (Kroger, Albertsons, Publix)
          • 1.6.2.1.2.3 Health System / Hospital Outpatient Pharmacies
          • 1.6.2.1.2.4 Independent Pharmacies
          • 1.6.2.1.2.5 Mail-Order Pharmacies
          • 1.6.2.1.2.6 Specialty / Central Fill Pharmacies
          • 1.6.2.1.2.7 Long-Term Care (LTC) and Defense-Related Pharmacies
          • 1.6.2.1.2.8 ePharmacies (Amazon, Capsule, Hims & Hers, etc.)
          • 1.6.2.1.2.9 Other Channels
          • 1.6.2.1.2.10 Aggregation & Triangulation
        • 1.6.2.1.3 Step 2: Determining Average Realized Price (ARP)
        • 1.6.2.1.4 Step 2: OTC Revenue
      • 1.6.2.2 Model 2: Company Market Share Analysis
        • 1.6.2.2.1 Step 1: Public Filings
        • 1.6.2.2.2 Step 2: Private & Independent Estimates
        • 1.6.2.2.3 Step 3: Market Share Allocation
      • 1.6.2.3 CAGR/Forecasting Calculations & Assumptions
        • 1.6.2.3.1 Key Forecasting Drivers and Weights
        • 1.6.2.3.2 Scenario Framework (2025-2033)
        • 1.6.2.3.3 Factor-Based Impact Assessment
    • 1.6.3 Estimation Process: Pharmacy Type Split By Catchment Area
      • 1.6.3.1 Data Sources
      • 1.6.3.2 Estimation Process
    • 1.6.4 Estimation Process: Pharmacy Type Split By Product Form
    • 1.6.5 Company-Level Metric's Estimation
      • 1.6.5.1 Financial Performance
        • 1.6.5.1.1 2024 Revenue & EBITDA (Pharmacy-Only)
        • 1.6.5.1.2 5-Year Forecast of Revenue & EBITDA
        • 1.6.5.1.3 Balance Sheet Health Indicators
      • 1.6.5.2 Volumes & Operations
        • 1.6.5.2.1 2024 Total Prescriptions; 5-Year Rx Forecast
        • 1.6.5.2.2 % Fulfilled via Central Fill; Volumes Split by Catchment Area
  • 1.7 List of Secondary Sources
  • 1.8 List of Abbreviations
  • 1.9 Research Objectives
    • 1.9.1 Objective - 1
    • 1.9.2 Objective - 2
    • 1.9.3 Objective - 3

Chapter 2. Executive Summary

  • 2.1 Market Snapshot
  • 2.2 Segment Outlook - I
  • 2.3 Segment Outlook- II
  • 2.4 Competitive Scenario

Chapter 3. U.S. Pharmacy Market - Industry Outlook

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent Market Outlook
    • 3.1.2 Related Market Outlook
      • 3.1.2.1 U.S. pharmacy benefit management market
  • 3.2 Market Dynamics
    • 3.2.1 Market Driver Analysis
      • 3.2.1.1 Increasing prevalence of chronic diseases
      • 3.2.1.2 Technological advancements
      • 3.2.1.3 Expanding health insurance coverage
      • 3.2.1.4 Increasing demand for specialty drugs
    • 3.2.2 Market Restraint Analysis
      • 3.2.2.1 Product recalls and lawsuits
      • 3.2.2.2 Lack of trained staff
    • 3.2.3 Market Opportunity Analysis
    • 3.2.4 Market Challange Analysis
  • 3.3 Regulatory Scenario & Reimbursement Outlook
    • 3.3.1 Regulatory Scenario
    • 3.3.2 Reimbursement Scenario
  • 3.4 Business Environment Analysis Tools
    • 3.4.1 Porter's Five Forces Analysis
    • 3.4.2 Pestle Analysis

Chapter 4. U.S. Pharmacy Market: Product Type Estimates & Trend Analysis

  • 4.1 U.S. Pharmacy Market: Product Type Segment Dashboard
  • 4.2 Product Type Movement & Market Share Analysis, 2024 & 2033
  • 4.3 U.S. Pharmacy Market Size & Forecast and Forecasts, By Product Type (USD Billion)
    • 4.3.1 Prescription
      • 4.3.1.1 Prescription market, 2021-2033 (USD Billion)
    • 4.3.2 Over-the-Counter (OTC)
      • 4.3.2.1 OTC market, 2021-2033 (USD Billion)

Chapter 5. U.S. Pharmacy Market: Type Estimates & Trend Analysis

  • 5.1 U.S. Pharmacy Market: Type Segment Dashboard
  • 5.2 Type Movement & Market Share Analysis, 2024 & 2033
  • 5.3 U.S. Pharmacy Market Size & Forecast and Forecasts, By Type, 2021 - 2033 (USD Billion)
  • 5.4 U.S. Pharmacy Market: Estimated Number of Pharmacies, By Type, 2021 - 2033 (Unit)
  • 5.5 U.S. Pharmacy Market: Estimated Prescription Volume, By Type, 2021 - 2033 (Million)
  • 5.6 U.S. Pharmacy Market: Estimated Prescription Volume, By Catchment Area, 2024 (%)
  • 5.7 U.S. Pharmacy Market: Estimated Prescription Volume, By Filled Prescriptions (TRx), 2024 (%)
    • 5.7.1 Retail Chains
      • 5.7.1.1 Retail chains market, 2021 - 2033 (USD Billion)
    • 5.7.2 Supermarket Pharmacies
      • 5.7.2.1 Supermarket pharmacies market, 2021 - 2033 (USD Billion)
    • 5.7.3 Health System / Hospital Pharmacy
      • 5.7.3.1 Health system / Hospital pharmacy market, 2021 - 2033 (USD Billion)
    • 5.7.4 Independent Pharmacies
      • 5.7.4.1 Independent pharmacies market, 2021 - 2033 (USD Billion)
    • 5.7.5 Mail-Order Pharmacies
      • 5.7.5.1 Mail-order pharmacy market, 2021 - 2033 (USD Billion)
    • 5.7.6 Specialty / Central Fill Pharmacies
      • 5.7.6.1 Specialty / central fill pharmacies market, 2021 - 2033 (USD Billion)
    • 5.7.7 Long-Term Care And Defense-Related Pharmacies
      • 5.7.7.1 Long-term care and defense-related pharmacies market, 2021 - 2033 (USD Billion)
    • 5.7.8 Epharmacy
      • 5.7.8.1 ePharmacy market, 2021 - 2033 (USD Billion)
    • 5.7.9 Others
      • 5.7.9.1 Others market, 2021 - 2033 (USD Billion)

Chapter 6. U.S. Pharmacy Market Competitive Analysis

  • 6.1 Company Categorization
  • 6.2 Estimated Company Market Share Analysis, 2024
    • 6.2.1 CVS Pharmacy
      • 6.2.1.1 Company Overview
      • 6.2.1.2 Financial Performance
        • 6.2.1.2.1 Revenue (pharmacy-only where available/estimable), 2024 - 2029 (USD Million)
        • 6.2.1.2.2 EBITDA (%) & EBITDA Margin (2024)
        • 6.2.1.2.3 Balance sheet health metrics (2024)
      • 6.2.1.3 Volumes & Operations
        • 6.2.1.3.1 Estimated prescription volumes; 2024 - 2029 (Million)
        • 6.2.1.3.2 % of prescriptions fulfilled via central fill (2024)
        • 6.2.1.3.3 % of prescriptions fulfilled by catchment areas (2024)
      • 6.2.1.4 Value Chain Position
        • 6.2.1.4.1 Current wholesaler(s), distributor(s), and GPO affiliations (if applicable)
        • 6.2.1.4.2 Ownership (public/private), parent/subsidiaries, recent M&A divestments
      • 6.2.1.5 Central Fulfillment (if used/planned)
        • 6.2.1.5.1 Strategy
        • 6.2.1.5.2 Requirements
        • 6.2.1.5.3 Technology provider(s) and hardware/automation
        • 6.2.1.5.4 Partnerships
      • 6.2.1.6 Strategy Mapping/ Major Deals & Strategic Alliances Analysis
    • 6.2.2 Walgreens Boots Alliance, Inc.
      • 6.2.2.1 Company Overview
      • 6.2.2.2 Financial Performance
        • 6.2.2.2.1 Revenue (pharmacy-only where available/estimable), 2024 - 2029 (USD Million)
        • 6.2.2.2.2 EBITDA (%) & EBITDA Margin (2024)
        • 6.2.2.2.3 Balance sheet health metrics (2024)
      • 6.2.2.3 Volumes & Operations
        • 6.2.2.3.1 Estimated prescription volumes; 2024 - 2029 (Million)
        • 6.2.2.3.2 % of prescriptions fulfilled via central fill (2024)
        • 6.2.2.3.3 % of prescriptions fulfilled by catchment areas (2024)
      • 6.2.2.4 Value Chain Position
        • 6.2.2.4.1 Current wholesaler(s), distributor(s), and GPO affiliations (if applicable)
        • 6.2.2.4.2 Ownership (public/private), parent/subsidiaries, recent M&A divestments
      • 6.2.2.5 Central Fulfillment (if used/planned)
        • 6.2.2.5.1 Strategy
        • 6.2.2.5.2 Requirements
        • 6.2.2.5.3 Technology provider(s) and hardware/automation
        • 6.2.2.5.4 Partnerships
      • 6.2.2.6 Strategy Mapping/ Major Deals & Strategic Alliances Analysis
    • 6.2.3 Scriptco Pharmacy
      • 6.2.3.1 Company Overview
      • 6.2.3.2 Financial Performance
        • 6.2.3.2.1 Revenue (pharmacy-only where available/estimable), 2024 - 2029 (USD Million)
        • 6.2.3.2.2 EBITDA (%) & EBITDA Margin (2024)
        • 6.2.3.2.3 Balance sheet health metrics (2024)
      • 6.2.3.3 Volumes & Operations
        • 6.2.3.3.1 Estimated prescription volumes; 2024 - 2029 (Million)
        • 6.2.3.3.2 % of prescriptions fulfilled via central fill (2024)
      • 6.2.3.4 Value Chain Position
        • 6.2.3.4.1 Current wholesaler(s), distributor(s), and GPO affiliations (if applicable)
        • 6.2.3.4.2 Ownership (public/private), parent/subsidiaries, recent M&A divestments
      • 6.2.3.5 Central Fulfillment (if used/planned)
        • 6.2.3.5.1 Strategy
        • 6.2.3.5.2 Requirements
        • 6.2.3.5.3 Technology provider(s) and hardware/automation
        • 6.2.3.5.4 Partnerships
      • 6.2.3.6 Strategy Mapping/ Major Deals & Strategic Alliances Analysis
    • 6.2.4 Walmart Pharmacy
      • 6.2.4.1 Company Overview
      • 6.2.4.2 Financial Performance
        • 6.2.4.2.1 Revenue (pharmacy-only where available/estimable), 2024 - 2029 (USD Million)
        • 6.2.4.2.2 EBITDA (%) & EBITDA Margin (2024)
        • 6.2.4.2.3 Balance sheet health metrics (2024)
      • 6.2.4.3 Volumes & Operations
        • 6.2.4.3.1 Estimated prescription volumes; 2024 - 2029 (Million)
        • 6.2.4.3.2 % of prescriptions fulfilled via central fill (2024)
        • 6.2.4.3.3 % of prescriptions fulfilled by catchment areas (2024)
      • 6.2.4.4 Value Chain Position
        • 6.2.4.4.1 Current wholesaler(s), distributor(s), and GPO affiliations (if applicable)
        • 6.2.4.4.2 Ownership (public/private), parent/subsidiaries, recent M&A divestments
      • 6.2.4.5 Central Fulfillment (if used/planned)
        • 6.2.4.5.1 Strategy
        • 6.2.4.5.2 Requirements
        • 6.2.4.5.3 Technology provider(s) and hardware/automation
        • 6.2.4.5.4 Partnerships
      • 6.2.4.6 Strategy Mapping/ Major Deals & Strategic Alliances Analysis
    • 6.2.5 Avita Pharmacy
      • 6.2.5.1 Company Overview
      • 6.2.5.2 Financial Performance
        • 6.2.5.2.1 Revenue (pharmacy-only where available/estimable), 2024 - 2029 (USD Million)
        • 6.2.5.2.2 EBITDA (%) & EBITDA Margin (2024)
        • 6.2.5.2.3 Balance sheet health metrics (2024)
      • 6.2.5.3 Volumes & Operations
        • 6.2.5.3.1 Estimated prescription volumes; 2024 - 2029 (Million)
        • 6.2.5.3.2 % of prescriptions fulfilled via central fill (2024)
      • 6.2.5.4 Value Chain Position
        • 6.2.5.4.1 Current wholesaler(s), distributor(s), and GPO affiliations (if applicable)
        • 6.2.5.4.2 Ownership (public/private), parent/subsidiaries, recent M&A divestments
      • 6.2.5.5 Central Fulfillment (if used/planned)
        • 6.2.5.5.1 Strategy
        • 6.2.5.5.2 Requirements
        • 6.2.5.5.3 Technology provider(s) and hardware/automation
        • 6.2.5.5.4 Partnerships
      • 6.2.5.6 Strategy Mapping/ Major Deals & Strategic Alliances Analysis
    • 6.2.6 The Kroger Co.
      • 6.2.6.1 Company Overview
      • 6.2.6.2 Financial Performance
        • 6.2.6.2.1 Revenue (pharmacy-only where available/estimable), 2024 - 2029 (USD Million)
        • 6.2.6.2.2 EBITDA (%) & EBITDA Margin (2024)
        • 6.2.6.2.3 Balance sheet health metrics (2024)
      • 6.2.6.3 Volumes & Operations
        • 6.2.6.3.1 Estimated prescription volumes; 2024 - 2029 (Million)
        • 6.2.6.3.2 % of prescriptions fulfilled via central fill (2024)
        • 6.2.6.3.3 % of prescriptions fulfilled by catchment areas (2024)
      • 6.2.6.4 Value Chain Position
        • 6.2.6.4.1 Current wholesaler(s), distributor(s), and GPO affiliations (if applicable)
        • 6.2.6.4.2 Ownership (public/private), parent/subsidiaries, recent M&A divestments
      • 6.2.6.5 Central Fulfillment (if used/planned)
        • 6.2.6.5.1 Strategy
        • 6.2.6.5.2 Requirements
        • 6.2.6.5.3 Technology provider(s) and hardware/automation
        • 6.2.6.5.4 Partnerships
      • 6.2.6.6 Strategy Mapping/ Major Deals & Strategic Alliances Analysis
    • 6.2.7 Albertsons Companies, Inc.
      • 6.2.7.1 Company Overview
      • 6.2.7.2 Financial Performance
        • 6.2.7.2.1 Revenue (pharmacy-only where available/estimable), 2024 - 2029 (USD Million)
        • 6.2.7.2.2 EBITDA (%) & EBITDA Margin (2024)
        • 6.2.7.2.3 Balance sheet health metrics (2024)
      • 6.2.7.3 Volumes & Operations
        • 6.2.7.3.1 Estimated prescription volumes; 2024 - 2029 (Million)
        • 6.2.7.3.2 % of prescriptions fulfilled via central fill (2024)
        • 6.2.7.3.3 % of prescriptions fulfilled by catchment areas (2024)
      • 6.2.7.4 Value Chain Position
        • 6.2.7.4.1 Current wholesaler(s), distributor(s), and GPO affiliations (if applicable)
        • 6.2.7.4.2 Ownership (public/private), parent/subsidiaries, recent M&A divestments
      • 6.2.7.5 Central Fulfillment (if used/planned)
        • 6.2.7.5.1 Strategy
        • 6.2.7.5.2 Requirements
        • 6.2.7.5.3 Technology provider(s) and hardware/automation
        • 6.2.7.5.4 Partnerships
      • 6.2.7.6 Strategy Mapping/ Major Deals & Strategic Alliances Analysis
    • 6.2.8 Costco Wholesale Corporation.
      • 6.2.8.1 Company Overview
      • 6.2.8.2 Financial Performance
        • 6.2.8.2.1 Revenue (pharmacy-only where available/estimable), 2024 - 2029 (USD Million)
        • 6.2.8.2.2 EBITDA (%) & EBITDA Margin (2024)
        • 6.2.8.2.3 Balance sheet health metrics (2024)
      • 6.2.8.3 Volumes & Operations
        • 6.2.8.3.1 Estimated prescription volumes; 2024 - 2029 (Million)
        • 6.2.8.3.2 % of prescriptions fulfilled via central fill (2024)
        • 6.2.8.3.3 % of prescriptions fulfilled by catchment areas (2024)
      • 6.2.8.4 Value Chain Position
        • 6.2.8.4.1 Current wholesaler(s), distributor(s), and GPO affiliations (if applicable)
        • 6.2.8.4.2 Ownership (public/private), parent/subsidiaries, recent M&A divestments
      • 6.2.8.5 Central Fulfillment (if used/planned)
        • 6.2.8.5.1 Strategy
        • 6.2.8.5.2 Requirements
        • 6.2.8.5.3 Technology provider(s) and hardware/automation
        • 6.2.8.5.4 Partnerships
      • 6.2.8.6 Strategy Mapping/ Major Deals & Strategic Alliances Analysis
    • 6.2.9 Sam's West, Inc.
      • 6.2.9.1 Company Overview
      • 6.2.9.2 Value Chain Position
        • 6.2.9.2.1 Current wholesaler(s), distributor(s), and GPO affiliations (if applicable)
        • 6.2.9.2.2 Ownership (public/private), parent/subsidiaries, recent M&A divestments
      • 6.2.9.3 Central Fulfillment (if used/planned)
        • 6.2.9.3.1 Strategy
        • 6.2.9.3.2 Requirements
        • 6.2.9.3.3 Technology provider(s) and hardware/automation
        • 6.2.9.3.4 Partnerships
      • 6.2.9.4 Strategy Mapping/ Major Deals & Strategic Alliances Analysis

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviation
  • Table 3 Specialty Drug Expenditures, 2016 - 2021
  • Table 4 U.S. Pharmacy Market Revenue Estimates and Forecast, By Product Type, 2021 - 2033 (USD Billion)
  • Table 5 U.S. Pharmacy Market Revenue Estimates and Forecast, By Type, 2021 - 2033 (USD Billion)
  • Table 6 U.S. Pharmacy Market: Estimated Number of Pharmacies, By Type, 2021 - 2033 (Unit)
  • Table 7 U.S. Pharmacy Market: Estimated Prescription Volume, By Type, 2021 - 2033 (Million)
  • Table 8 U.S. Pharmacy Market Revenue Estimates and Forecast, By Ownership, 2021 - 2033 (USD Billion)
  • Table 9 U.S. Pharmacy Market: Estimated Prescription Volume, By Catchment Area, 2024 (%)
  • Table 10 U.S. Pharmacy Market: Estimated Prescription Volume, By Filled Prescriptions (TRX), 2024 (%)

List of Figures

  • Fig. 1 U.S. Pharmacy Market Segmentation
  • Fig. 2 Market Research Process
  • Fig. 3 Information Procurement
  • Fig. 4 Primary Research Pattern
  • Fig. 5 Market Research Approaches
  • Fig. 6 Value-Chain-Based Sizing & Forecasting
  • Fig. 7 Market Formulation & Validation
  • Fig. 8 Market Snapshot
  • Fig. 9 Segment Outlook-I
  • Fig. 10 Segment Outlook-II
  • Fig. 11 Competitive Scenario
  • Fig. 12 U.S. Pharmacy Market: Parent Market Outlook
  • Fig. 13 U.S. Pharmacy Market: Ancillary/Related Market Outlook
  • Fig. 14 U.S. Pharmacy Market Dynamics
  • Fig. 15 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 16 Estimated New Cancer Cases, 2024
  • Fig. 17 Estimated US Prevalence of Stroke, 2018 - 2030
  • Fig. 18 Estimated US Prevalence of Prostate Cancer, 2018 - 2030
  • Fig. 19 Estimated US Prevalence of Kidney Cancer, 2018 - 2030
  • Fig. 20 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 21 Number of Pharmacy Degrees Conferred 2018 - 2023 By Gender
  • Fig. 22 U.S. Pharmacy Market: Porter's Five Forces Analysis
  • Fig. 23 U.S. Pharmacy Market: PESTLE Analysis
  • Fig. 24 U.S. Pharmacy Market: Product Type Segment Dashboard
  • Fig. 25 U.S. Pharmacy Market: Product Type Market Share Analysis, 2024 & 2033
  • Fig. 26 Prescription Market, 2021 - 2033 (USD Billion)
  • Fig. 27 OTC Market, 2021 - 2033 (USD Billion)
  • Fig. 28 U.S. Pharmacy Market: Type Segment Dashboard
  • Fig. 29 U.S. Pharmacy Market: Type Market Share Analysis, 2024 & 2033
  • Fig. 30 Retail Pharmacy Market, 2021 - 2033 (USD Billion)
  • Fig. 31 Supermarket Pharmacies Market, 2021 - 2033 (USD Billion)
  • Fig. 32 Health System / Hospital Pharmacy Market, 2021 - 2033 (USD Billion)
  • Fig. 33 Independent Pharmacies Market, 2021 - 2033 (USD Billion)
  • Fig. 34 Mail-Order Pharmacy Market, 2021 - 2033 (USD Billion)
  • Fig. 35 Specialty / Central Fill Pharmacies Market, 2021 - 2033 (USD Billion)
  • Fig. 36 Long-Term Care and Defense-Related Pharmacies Market, 2021 - 2033 (USD Billion)
  • Fig. 37 E-pharmacy Market, 2021 - 2033 (USD Billion)
  • Fig. 38 Others Market, 2021 - 2033 (USD Billion)
  • Fig. 39 U.S. Pharmacy Market: Ownership Segment Dashboard
  • Fig. 40 U.S. Pharmacy Market: Ownership Market Share Analysis, 2024 & 2033
  • Fig. 41 Chain Pharmacy Market, 2021 - 2033 (USD Billion)
  • Fig. 42 Independent Pharmacy Market, 2021 - 2033 (USD Billion)
  • Fig. 43 Key Company Categorization
  • Fig. 44 Estimated Company Market Share Analysis, 2024